STAT Plus: Congressional committee to subpoena AbbVie in drug pricing investigation
A Congressional committee plans to subpoena AbbVie (ABBV) for documents about pricing practices for two of its best-selling medicines, following the drug maker’s failure to provide information lawmakers requested when an investigation was launched in January 2019.
At the time, the House Committee on Oversight and Reform sought data from a dozen large pharmaceutical companies about their pricing tactics for some of the most expensive medicines in response to nationwide angst over the rising cost of prescription drugs. AbbVie was asked for information about Humira, its rheumatoid arthritis treatment, and Imbruvica, a medication for lymphoma.
